Log In Sign up
The largest database of trusted experimental protocols

Pe conjugated anti trop 2 antibody

Manufactured by Thermo Fisher Scientific
Visit Supplier

The PE-conjugated anti-Trop-2 antibody is a laboratory reagent used for the detection and analysis of the Trop-2 protein in biological samples. It consists of a phycoerythrin (PE) fluorescent dye conjugated to an antibody that specifically binds to the Trop-2 protein.

Automatically generated - may contain errors

Lab products found in correlation

Quantibrite pe beads, by BD (2 mentions) Cellquest pro software, by Tree Star (1 mentions) Facscalibur flow cytometer, by BD (1 mentions) Accutase cell detachment solution, by BD (1 mentions)

2 protocols using pe conjugated anti trop 2 antibody

1

Quantification of Trop-2 Expression via Flow Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols
Expression of Trop-2 on the cell surface is based on flow cytometry. Briefly, cells were harvested with Accutase Cell Detachment Solution (Becton Dickinson (BD); Franklin Lakes, NJ; Cat. No. 561527) and assayed for Trop-2 expression using QuantiBRITE PE beads (BD Cat. No. 340495) and a PE-conjugated anti-Trop-2 antibody (eBiosciences, Cat. No. 12-6024) following the manufacturer's instructions. Data were acquired on a FACSCalibur Flow Cytometer (BD) with CellQuest Pro software, with analysis using Flowjo software (Tree Star; Ashland OR).
Goldenberg D.M., Cardillo T.M., Govindan S.V., Rossi E.A, & Sharkey R.M. (2015). Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget, 6(26), 22496-22512.
+ Open protocol
+ Expand
2

Quantifying Trop-2 Cell Surface Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
Expression of Trop-2 on the cell surface is based on flow cytometry making use of QuantiBRITE PE beads (BD Cat. No. 340495) and a PE-conjugated anti-Trop-2 antibody (eBiosciences, Cat. No. 12-6024), as described previously [26 (link)] and presented in the Supplementary Materials.
Cardillo T.M., Zalath M.B., Arrojo R., Sharkey R.M., Govindan S.V., Chang C.H, & Goldenberg D.M. (2024). Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas. Oncotarget, 15, 144-158.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!